NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada

NDA FilingPrimeCPositive

AI Analysis

Summary

NeuroSense Therapeutics completed the Pre-NDS process with Health Canada for its ALS drug PrimeC, with alignment on submission content and structure ahead of a planned December 2026 filing.

Outcome Details

Completed Pre-NDS process with Health Canada alignment on submission content and structure

Importance:6/10

Sentiment:

0.60

regulatoryNDA filingHealth CanadaALSlate-stage

Related Companies

$NRSN $HIT

Read the original article

Published by PR Newswire Biotech on August 6, 2026 3:29 PM

Read Original